These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Liver size and indices of drug metabolism in alcoholics. Pirttiaho HI; Sotaniemi EA; Ahlqvist J; Pitkänen U; Pelkonen RO Eur J Clin Pharmacol; 1978 Mar; 13(1):61-7. PubMed ID: 639835 [TBL] [Abstract][Full Text] [Related]
9. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease. Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397 [TBL] [Abstract][Full Text] [Related]
10. Triacylglycerol metabolism in the phenobarbital-treated rat. Goldberg DM; Roomi MW; Yu A; Roncari DA Biochem J; 1981 Apr; 196(1):337-46. PubMed ID: 7306075 [TBL] [Abstract][Full Text] [Related]
11. Plasma high-density lipoproteins and liver lipids and proteins in man. Relation to hepatic histology and microsomal enzyme induction. Luoma PV; Savolainen MJ; Sotaniemi EA; Pelkonen RO; Arranto AJ; Ehnholm C Acta Med Scand; 1983; 214(2):103-9. PubMed ID: 6624542 [TBL] [Abstract][Full Text] [Related]
12. Drug and fatty acid hydroxylation by solubilized human liver microsomal cytochrome P-450-phospholipid requirement. Kaschnitz RM; Coon MJ Biochem Pharmacol; 1975 Jan; 24(2):295-7. PubMed ID: 1111541 [No Abstract] [Full Text] [Related]
13. Age-related changes in hepatic microsomal drug metabolism are substrate selective. Rikans LE; Notley BA J Pharmacol Exp Ther; 1982 Mar; 220(3):574-8. PubMed ID: 7062268 [TBL] [Abstract][Full Text] [Related]
14. Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays. Sotaniemi EA; Pelkonen RO; Puukka M Eur J Clin Pharmacol; 1980 Apr; 17(4):267-74. PubMed ID: 6105079 [No Abstract] [Full Text] [Related]
15. Drug metabolism in man: in vivo and in vitro correlations. Sotaniemi EA; Pelkonen RO; Ahokas J; Ahlqvist J; Hokkanen OT Arch Toxicol Suppl; 1978; (1):339-42. PubMed ID: 277127 [TBL] [Abstract][Full Text] [Related]
16. Effect of cobalt protoporphyrin on hepatic drug-metabolizing enzymes. Specificity for cytochrome P-450. Spaethe SM; Jollow DJ Biochem Pharmacol; 1989 Jun; 38(12):2027-38. PubMed ID: 2742604 [TBL] [Abstract][Full Text] [Related]
17. Liver microsomal drug-metabolizing enzyme system: functional components and their properties. Lu AY Fed Proc; 1976 Nov; 35(13):2460-3. PubMed ID: 824157 [TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Bartoli A; Gatti G; Cipolla G; Barzaghi N; Veliz G; Fattore C; Mumford J; Perucca E Epilepsia; 1997 Jun; 38(6):702-7. PubMed ID: 9186253 [TBL] [Abstract][Full Text] [Related]
19. Effect of Schistosoma mansoni infection on the hepatic drug-metabolizing capacity of mice. Cha YN; Edwards R J Pharmacol Exp Ther; 1976 Nov; 199(2):432-40. PubMed ID: 185361 [TBL] [Abstract][Full Text] [Related]
20. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. Salmela PI; Sotaniemi EA; Pelkonen RO Diabetes; 1980 Oct; 29(10):788-94. PubMed ID: 7439538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]